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Abstract: Only a few studies have examined the efficacy and safety of smoking cessation 
programmes in patients with mental disorders. The aim of this paper is to describe in detail 
the methodology used in the study as well as the Multi-component Smoking Cessation 
Support Programme in terms of pharmacological treatments and psychological 
interventions. An open-label 9-month follow-up study was conducted in Spain. A total of 
82 clinically stable outpatients with schizophrenia, schizoaffective or bipolar disorder were 
OPEN ACCESS
Int. J. Environ. Res. Public Health 2014, 11 374 
 
 
enrolled. Treatment consisted of a programme specifically developed by the research team 
for individuals with severe mental disorders. The programme consisted of two phases:  
(1) weekly individual motivational therapy for 4–12 weeks, and (2) a 12-week active 
treatment phase. During this phase, at each study visit patients received a one- or two-week 
supply of medication (transdermal nicotine patches, varenicline or bupropion) with 
instructions on how to take it, in addition to group psychotherapy for smoking cessation. 
Evaluations were performed: (1) at the time of enrolment in the study, (2) during the  
12-week active treatment phase of the study (weekly for the first 4 weeks and then 
biweekly), and (3) after the end of this phase (two follow-up assessments at weeks 12 and 24). 
Evaluations included: (1) smoking history, (2) substance use, (3) psychopathology,  
(4) adverse events, and (5) laboratory tests. The importance of this study lies in addressing 
a topical issue often ignored by psychiatrists: the unacceptably high rates of tobacco use in 
patients with severe mental disorders. 
Keywords: schizophrenia; bipolar disorder; transdermal nicotine patches;  
varenicline; bupropion 
 
1. Introduction 
Although smoking rates are declining in the general population in developed countries [1],  
patients with long-standing mental health disorders are almost twice as likely to smoke as people 
without such problems [2]. In fact smoking prevalence rates among people with mental disorders 
(schizophrenia, mood and anxiety disorders) are two to four times higher than in the general 
population [3,4]. Prevalence is greatest in patients with schizophrenia with rates around 64% followed 
by patients with bipolar disorder, with rates around 44% [5]. In Spain the reported tobacco use rate in 
patients with schizophrenia was 54.4% [6] and 51.5% in patients with bipolar disorder [7,8].  
These rates are practically twice that of the general Spanish population (26.4%) [9].  
This exceptionally high prevalence, explained by several biological and psychosocial factors, 
contributes to the high rates of medical morbidity and mortality in patients with severe mental 
disorders [6,7,10,11]. Life expectancy was found to be 25 years lower in patients with mental illnesses, 
mainly due to tobacco-related diseases [12]. In this respect the Spanish Consensus on Physical Health 
of Patients with Schizophrenia [13] and with Bipolar Disorder [14] rank respiratory disorders 
(standardized mortality ratio of 3–7 in patients with bipolar disorder) followed by cardiovascular 
disease as the leading causes of the increased mortality rates in these patients. With respect to 
morbidity, tobacco use seems to be one of the most important risk factors for the greater risk of 
coronary disease both in patients with schizophrenia [6,15–17] and bipolar disorder [7]. 
In addition to its negative impact on physical health, tobacco use has been associated with more 
excitement and agitation symptoms [18,19], greater severity of global psychopathology as measured 
by the Clinical General Impression (CGI) scale [6], and positive psychotic symptoms [6,20] in patients 
with schizophrenia, although the effect size was small [6]. In patients with bipolar disorders the results 
are controversial; while some studies showed tobacco use to be associated with greater disorder 
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severity [21,22] others did not [7]. Recently a relationship was also reported between smoking  
and use of a greater number of psychopharmaceuticals for the treatment of bipolar disorder [7]. 
Furthermore, an association was found between tobacco use and greater attempted suicide rates in 
patients with bipolar disorders [23,24] and with schizophrenia [25]. Some studies have also reported 
beneficial effects of tobacco on patients’ mental health. Thus improvements in negative symptoms [20,26], 
spatial working memory and attention deficit [27], and sensory gating [28] have been reported. 
However we believe that these beneficial effects do not justify maintaining the smoking habit in this 
population, as tobacco is associated with more than 4,000 toxins and 60 carcinogens, and nicotine can 
be delivered more safely through approved drugs.  
Studies on the smoking patterns of individuals with severe mental disorders have shown that they 
started smoking an average of 5 years prior to illness onset [29–31], smoked a large number of 
cigarettes per day [29], had higher plasma nicotine levels than smokers without mental disorders [32,33] 
and were more nicotine-dependent than general population [16,34–36]. 
While smokers with severe mental disorders have quite low smoking cessation rates, they have 
demonstrated high levels of motivation to quit [37,38], persistent attempts [39] and good tolerance of 
short-term nicotine abstinence without significant clinical exacerbation [40–43]. Despite all the above, 
only a few studies have examined the efficacy and safety of smoking cessation programmes in patients 
with mental disorders. For this reason we decided to develop a Multi-component Smoking Cessation 
Support Programme (McSCSP) tailored to the specific characteristics of individuals with severe 
mental disorders, as recommended by the European Association of Psychiatry (EPA) in its Position 
Statement on Smoking and Strategies for Smoking Cessation in People with Mental Illness [44],  
and to determine its clinical effectiveness. The McSCSP consisted of two phases: (1) weekly individual 
motivational therapy for 4–12 weeks, and (2) a 12-week active treatment phase. During this phase,  
at each study visit patients received a one- or two-week supply of medication with instructions on how 
to take it, in addition to group psychotherapy for smoking cessation. 
The aim of this paper is to describe in detail the methodology used in the study, i.e., inclusion and 
exclusion criteria, clinical evaluations including smoking history, substance use, psychopathology, 
adverse events, anthropometrics, vital signs, and laboratory tests, as well as the McSCSP in terms of 
pharmacological treatments and psychological interventions. 
2. Methods 
2.1. Study Design 
This is a non-randomized, open-label (both the researchers and participants know which treatment is 
being administered), 9-month follow-up study conducted at three sites in Spain (Oviedo, Vitoria,  
and Jaén) between March 2011 and June 2013. The study was conducted at two Mental Health Centres 
(Oviedo and Jaén) and at the Refractory Psychosis Unit where outpatients from the city of Vitoria were 
referred for the study. 
The Clinical Research Ethics Committee of Hospital Universitario Central de Asturias in Oviedo,  
Spain approved the study protocol. Written informed consent was obtained from all subjects prior  
to enrolment. 
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2.2. Subjects 
The sample size needed for this study was determined using the EpiInfo v.6.0 program.  
Considering a population of 150 patients with severe mental disorder for each of the three psychiatrists 
participating in the study, a 6-month successful smoking cessation rate of 12% of the patients at six 
months, and a confidence interval level of 95%, a sample size of n = 23 per centre is needed to achieve 
the stated goals. 
A total of 82 outpatients with schizophrenia, schizoaffective or bipolar disorder on maintenance 
treatment were enrolled in the study (74.4% schizophrenia or schizoaffective disorder and 25.6 bipolar 
disorder). Four of them dropped-out before initiating the active treatment phase. Of the 78 patients 
who were included in the active phase of treatment, 50% received varenicline, 46.2% 24-hour nicotine 
transdermal patches, and 3.8% bupropion SR. A total of 62.8% of the patients completed the 12-week 
active treatment phase. There was no statistically significant differences in the retention rate among the 
three drugs (see Figure 1). 
Figure 1. Patients’ disposition. 
 
Inclusion criteria were: (1) patients with a confirmed DSM-IV diagnosis of schizophrenia, 
schizoaffective or bipolar disorder, clinically stable (i.e., without hospitalization or acute exacerbation) 
in the six months prior to enrolment in the study and on maintenance treatment; (2) currently smoking 
15 or more cigarettes/day without a period of smoking abstinence longer than one month during the 
previous year; (3) Fagerström Test for Nicotine Dependence score ≥4 (moderate); (4) breath carbon 
monoxide (CO) level >9 particles per million (ppm); (5) between 18 and 65 years of age;  
(6) without suicidal ideation; and (7) written informed consent to participate in the study. 
Patients were excluded if they had (1) a total score >70 on the Positive and Negative Symptoms 
Scale (PANSS) for patients with schizophrenia, or >14 on the Hamilton Depression Rating Scale 
(HDRS) or >6 on the Young Mania Rating Scale (YMRS) for patients with bipolar disorder;  
(2) serious suicidal behaviour or thoughts in the last six months; (3) severe and unstable somatic illness 
including but not limited to acute myocardial infarction, unstable arrhythmia, stroke;  
(4) history of organic brain damage including epilepsy, tumours, head injuries with significant 
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cognitive impairment; (5) significant renal impairment (creatinine ≥ 1.5 mg/dL); and (6) liver function 
tests more than twice the upper limit of normal values. 
2.3. Diagnostic Interview 
Diagnosis was confirmed by the psychiatrists participating in the study using the Schizophrenia, 
Schizoaffective and Bipolar sections of the Spanish version of the Structured Clinical Interview for 
DSM-IV Axis I Disorders (SCID-I) [45]. 
2.4. Demographic and Clinical Data 
Demographic and clinical data were collected at baseline. Demographic data included: birth date, 
age, gender, civil status, educational level, main occupation, and current working status. Clinical data 
included: primary diagnosis, secondary diagnosis, length of illness, first episode, previous suicide 
attempts, and current psychopharmacological treatment. Changes in psychopharmacological treatment 
were recorded at every visit.  
2.5. Clinical Evaluations 
Psychometric and biological evaluations included smoking history, substance use, psychopathology, 
adverse events, anthropometrics, vital signs and laboratory tests (see Table 1). For all instruments used 
in the study we employed the validated Spanish versions with the exception of the Columbia Suicide 
Severity Rating Scale (CSSRS), which is currently being validated (Project PI: Pilar A. Saiz),  
and the Richmond test which, although it has not been validated in Spanish, is widely used in our 
country [46]. 
Table 1. Psychometric and biological evaluations. 
Area of Assessment 
Psychometric Instruments/ 
Biological Parameters 
Inclusion  
Criteria 
Exclusion 
Criteria 
Smoking history 
Pattern of  
tobacco use 
 Age at first use 
 Number of years smoked 
 Smoking pack-year (SPY) 
 Cigarette brand 
 Cigarettes per day (CPD) 
 Breath carbon monoxide  
(CO) level 
 
 
 
 
 ≥15 cigarettes/day 
 >9 ppm 
 
Nicotine 
dependence 
 Fagerström Test for Nicotine 
Dependence (FTND) 
 Glover-Nilsson Smoking 
Behavioral Questionnaire  
 Total score ≥ 4  
Motivation to quit 
 Richmond test 
 University of Rhode Island 
Change Assessment (URICA) 
scale 
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Table 1. Cont. 
Area of Assessment 
Psychometric Instruments/ 
Biological Parameters 
Inclusion  
Criteria 
Exclusion  
Criteria 
Substance use 
Caffeine  Daily consumption   
Other 
 Drug Use Table—Individual 
Substances of the Addiction 
Severity Index 6th version 
(ASI6) 
  
Psychopathology 
Schizophrenia or 
schizoaffective 
patients 
 Positive and Negative 
Syndrome Scale (PANSS) 
  Total score > 70
Patients with  
bipolar disorder 
 Hamilton Depression  
Rating Scale (HDRS) 
 Young Mania Rating  
Scale (YMRS) 
  Total score > 14
 Total score > 6 
Both types  
of patients 
 SCID-I: Schizophrenia, 
Schizoaffective and  
Bipolar sections 
 Columbia Suicide Severity 
Rating Scale (CSSRS) 
 Clinical Global  
Impression (CGI) 
 Meeting 
criteria for 
one disorder 
 Serious suicidal 
behaviours or 
thoughts 
Adverse events 
 UKU Side Effects Rating  
Scale (UKU) 
  
Biological 
evaluation 
Anthropometrics 
 Weight, height,  
body mass index (BMI),  
waist circumference 
  
Vital signs  Blood pressure, heart rate   
Laboratory tests 
 Renal function tests: 
creatinine, BUN, glomerular 
filtration rate  
 Liver function tests: aspartate 
aminotransferase (AST), 
alanine aminotransferase 
(ALT), gamma glutamyl 
transpeptidase (GGT), total 
bilirubin (TBIL) 
 Lipid profile: triglycerides, 
total cholesterol, HDL 
cholesterol, LDL cholesterol 
  Creatinine ≥ 1.5 
 
 Liver function 
tests > 2 × the 
upper limit of 
normal 
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2.5.1. Smoking History 
Pattern of tobacco use was described with the following parameters: age at first use, number of 
years smoked, pack-years, cigarette brand, cigarettes per day (CPD), and breath carbon monoxide 
(CO) level.  
Smoking packyears (SPY): Tobacco exposure has a cumulative effect so it is necessary to consider 
not only current consumption but also global lifetime consumption. SPY is a numerical value that 
represents the amount an individual has smoked over his/her life. The following formula is used to 
calculate it: (number of cigarettes per dayA  years of consumption of amountA/20) + (number of 
cigarettes per dayB  years of consumption of amountB/20) + ... + (number of cigarettes per dayn  years of 
consumption of amountn/20). A calculator can be downloaded from http://smokingpackyears.com/ 
calculate [47]. 
Cigarettes per day (CPD): The number of CPD can be considered a face valid measure of nicotine 
dependence with low predictive abstinence value [48]. As there is no consensus on how to best define 
“light” and “heavy” smokers, we classified subjects into three categories according to the following 
classification: self-reported CPD <10 = light smoker; 11–20 = moderate smoker; and >20 = heavy smoker. 
Breath CO levels: Breath CO was measured with a portable piCOsimpleTM Smokerlyzer® monitor 
(Bedfont Scientific Ltd., Kent, UK). In keeping with the majority of studies we used a cutoff point for 
current smokers of 9 ppm. Since smokers have diurnal variation in CO [49,50] it was measured 
between 9 a.m. and 11 a.m. 
Nicotine dependence: This was evaluated using the Fagerström Test for Nicotine Dependence 
(FTND) [50] and the Glover-Nilsson Smoking Behavioral Questionnaire [51]. The FTDN comprises 
six items that evaluate the degree of nicotine dependence. The FTDN total score ranges from 0 to 10 
and categorizes patients as having mild (0–3), moderate (4–7), and severe (8–10) nicotine dependence. 
It was recently recommended by the European Psychiatric Association for use in daily clinical  
practice [44]. 
The Glover-Nilsson test consists of 11 items that capture behavioural nicotine dependence.  
It classifies behavioural dependence into four levels according to total score: 0–11 = mild;  
12–22 = moderate; 23–33 = strong; 34–44 = very strong. 
Motivation to quit: The Richmond test [52] and the University of Rhode Island Change Assessment 
(URICA) scale [53] were used to measure the individual’s motivation to quit smoking and his/her 
readiness to change, respectively. The Richmond test is a 4-item instrument that evaluates motivation 
to quit smoking. Total score ranges between 0 and 10. Scores between 0 and 4 indicate low motivation; 
5–6 moderate motivation; and 7–10 high motivation to quit. 
The URICA is a 32-item scale that contains four 8-item subscales measuring the stages of change: 
Precontemplation (PC), Contemplation (C), Action (A), and Maintenance (M). A continuous  
“Readiness to Change” score can be obtained using the following formula [(Avg C + Avg A + Avg M) 
− Avg PC], where Avg represents the average score of each of the four subscales in order to evaluate 
an individual’s level of motivation for change. Since there are no normative scores for the Spanish 
population we decided to use subscale scores instead of the readiness to change score to determine 
each patient’s stage of the change. 
Int. J. Environ. Res. Public Health 2014, 11 380 
 
 
2.5.2. Substance Use  
The use of the following substances was assessed with the Drug Use Table—Individual Substances 
of the Spanish Addiction Severity Index 6th version (ASI6) [54]: marijuana, sedatives, cocaine, 
stimulants, hallucinogenics, heroin, methadone, other opiates, and inhalants. For each substance we 
determined the age at first use, years of regular use, if used 50 or more days (lifetime), use in past 30 days, 
and if used as treatment (last 30 days). In addition we recorded daily caffeine consumption by asking about 
daily consumption of coffee, tea, cola and energy drinks (Burn, Red Bull, Fire, etc.). Caffeine 
consumption was recorded as number of cups of coffee per day based on the following equivalence: 1 
cup of coffee = 1 energy drink = 2 cups of tea = 3 colas [55]. 
2.5.3. Psychopathology  
In patients with schizophrenia we used the PANSS [56], which measures the severity of positive, 
negative, and general psychopathology symptoms. In patients with bipolar disorder we used the  
HDRS [57] and the YMRS [58], which rate the severity of depressive and manic symptoms, 
respectively. In both types of patients we utilized the CGI [59] for assessing severity and change in 
global psychopathology, and the CSSRS to evaluate suicidal thoughts and behaviours. 
2.5.4. Adverse Events 
Unwanted side effects of pharmacological treatment were assessed by means of the UKU Side Effects 
Rating Scale (UKU) [60]. In addition, we will also get information about them through the psychometric 
ratings, anthropometric measures, laboratory results and spontaneous patient’ self-reports. 
2.5.5. Anthropometrics, Vital Signs, and Laboratory Tests 
Weight and height were measured without jackets and shoes. Body mass index (BMI) was 
calculated as body weight (kg) divided by the square of height (m2). Waist circumference was 
measured at the high point of the iliac crest and at the level of the umbilicus. Heart rate was measured 
as number of beats per minute using the wrist palpation method. Blood pressure consisted of a single 
seated determination. Blood samples were collected if patients confirmed having fasted for at least 8 h. 
Creatinine, BUN, glomerular filtration rate, aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma glutamyl transpeptidase (GGT), total bilirubin (TBIL), triglycerides, total cholesterol, 
and HDL and LDL cholesterol were tested. 
2.6. Assessments  
All subjects were evaluated at the time of enrolment in the study before starting the motivational 
therapy. During the 12-week active treatment phase patients were assessed weekly for the first 4 weeks 
and then biweekly. After the end of this phase, two follow-up assessments were done at weeks 12 and 
24 (study weeks 24 and 36 respectively). Table 2 displays the timing and the parameters evaluated. 
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Table 2. Task schedule. 
Study Phase Motivation Active Treatment Follow-up 
Visit number  
Week 
MV1 
w-12 to w-4
V0
w0
V1
w1
V2
w2
V3
w3
V4
w4
V5
w6
V6 
w8 
V7 
w10 
V8 
w12 
FU- 
V1 
w24
FU- 
V2 
w36
Inclusion/Exclusion criteria 
Informed consent 
Demographic data 
Clinical data 
SCID-I: Schizophrenia, 
Schizoaffective and Bipolar sections 
X 
X 
X 
X 
X 
           
Smoking history 
Pattern of tobacco use 
Cigarettes per day (CPD) 
Breath CO level 
Fagerström Test for Nicotine 
Dependence (FTND) 
Glover-Nilsson Smoking Behavioral 
Questionnaire 
Richmond test 
University of Rhode Island Change 
Assessment (URICA) scale 
 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
X
X
X
X
X
 
 
 
X
X
X
X
 
 
 
X
X
X
X
 
 
 
X
X
X
X
 
 
 
X 
X 
X 
X 
 
 
 
X
X
X
X
 
 
 
X
X
X
X
 
 
 
X 
X 
X 
X 
 
 
 
X 
X 
X 
X 
 
 
 
X 
X 
X 
X 
 
 
 
X 
X 
X 
X 
 
Substance use 
Daily caffeine consumption 
Drug Use, Table from the Addiction 
Severity Index 6th version (ASI6) 
 
X 
X 
 
 
X
X
 
 
X
X
 
 
X
X
 
 
X
X
 
 
X 
X 
 
 
X
X
 
 
X
X
 
 
X 
X 
 
 
X 
X 
 
 
X 
X 
 
 
X 
X 
 
Psychopathology 
Positive and Negative Syndrome 
Scale (PANSS) 
Hamilton Depression Rating Scale 
(HDRS) 
Young Mania Rating Scale (YMRS) 
Columbia Suicide Severity Rating 
Scale (CSSRS) 
Clinical Global Impression (CGI) 
Severity 
Change 
 
X 
X 
X 
X 
X 
X 
 
 
X
X
X
X
X
X
 
 
X
X
X
X
X
X
X
 
 
X
X
X
X
X
X
X
 
 
X
X
X
X
X
X
X
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X
X
X
X
X
X
X
 
 
X
X
X
X
X
X
X
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Adverse events 
UKU Side Effects Rating Scale 
(UKU) 
 
X 
 
 
X
 
 
X
 
 
X
 
 
X
 
 
X 
 
 
X
 
 
X
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
Biological evaluation 
Anthropometrics and vital signs 
Laboratory tests 
 
X 
X 
 
X
 
 
X
 
 
X
 
 
X
 
 
X 
X 
 
X
 
 
X
 
 
X 
 
 
X 
X 
 
X 
X 
 
X 
X 
Notes: FU: follow-up; M: motivation; V: visit; w: week; w-12 to w-4: between 12 and 4 weeks before starting 
Active Treatment (V0, w0). 
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2.7. Statistical Plan  
We will determine short-term (at the end of the 12-week active treatment phase), and 3- and  
6-months after active treatment outcomes. The primary outcome measure will be smoking cessation,  
a composite measure formed by the patient's self-report of previous 7-day abstinence confirmed by 
breath CO levels ≤ 9 ppm. It will be also considered as main outcome measure the proportion of 
subjects with at least 50% reduction in the number of cigarettes per day. Secondary outcome measures 
will be safety, including changes in the symptoms of the primary illness, and tolerability. 
2.8. Treatment 
2.8.1. Pharmacological Treatment 
The pharmacological treatments used in the study were those approved for smoking cessation 
(bupropion sustained release, nicotine replacement therapy (transdermal patches) and varenicline) and 
considered first-line options by the US Public Health Service in 2008 [61]. Recently the European 
Psychiatric Association (EPA) [44] recommended drug treatment with nicotine, varenicline or bupropion 
for even a mild degree of tobacco dependence in every psychiatric patient. However, it should be 
pointed out that, in its Therapeutic Prescribing Guidelines, the Agencia Española de Medicamentos y 
Productos Sanitarios does not include varenicline among the drugs approved for smoking cessation and 
specifically contraindicates the use of bupropion in patients with bipolar disorder [62].  
For each patient the drug was chosen based on the clinical characteristics of his/her mental disorder, 
smoking pattern and previous smoking cessation experiences, somatic comorbidities and their 
pharmacologic treatments, as well as patient preference. Varenicline was given according to the usual 
schedule, i.e., 0.5 mg/day for the first 3 days, 0.5 mg BID on days 4–7, and 1 mg BID for the 
remaining 11 weeks. Bupropion SR was given as recommended, i.e., 150 mg/day for the first 6 days 
and 150 mg BID for the remaining treatment period. Twenty-four-hour nicotine transdermal patches were 
given to patients at doses of 14, 21, 28 or 35 mg based on their tobacco use during the last 12 weeks. 
In the case of psychopathological exacerbation or serious adverse events the pharmacological 
treatment was discontinued and the subject was withdrawn from the study.  
2.8.2. Psychological Interventions 
The study included two types of sequential psychological interventions. Firstly those patients 
willing to quit smoking and participate in the study received individual motivational therapy to prepare 
them for the active treatment phase. Secondly group psychotherapy was provided as part of the active 
treatment phase along with pharmacotherapy. 
Motivational therapy: Those smokers who wanted to quit received individual motivational therapy 
before entering the active treatment phase. The programme was flexible, lasting between 4 and 12 
sessions depending on each subject’s characteristics, and was based on the motivational interviewing 
technique [63]. Its main objective was to help patients move forward through the Stages of Change 
Model [64] to the stages of Contemplation or Action. The main issues addressed during the sessions were 
(1) pros and cons of smoking, (2) health and financial burden of smoking, and (3) concerns about quitting.  
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We included the financial burden of smoking because we believe that in patients with severe mental 
disorder this is a very important point as shown by Lawn [65]. Many of them are financially dependent 
on a mental disability benefit and spend a large part of their monthly income on cigarettes. 
Group therapy: A specific intensive 12-week manualized group therapy programme for individuals 
with severe mental was developed by the research team based on available smoking cessation 
guidelines and our own experience. The programme is suitable for delivery by healthcare providers 
experienced in working with patients with severe mental disorders and in conducting psychoeducational 
groups, including psychiatric nurses, psychologists and psychiatrists. Session content covered 
decisional balance, nicotine withdrawal and psychiatric symptoms, weight gain, control techniques, 
advantages and disadvantages of the pharmacological treatment options, improving adherence,  
and preventing relapses. In addition to group therapy, patients had to do homework that was reviewed 
at the beginning of the next session. Each treatment session lasted 60–75 min and included six to eight 
patients who achieved the Contemplation or Action stages of the Prochaska and DiClemente Model [64].  
3. Discussion 
This study tries to determine the effectiveness of a McSCSP specifically developed for use in 
individuals with severe mental disorders. The importance of this study lies in addressing a topical issue 
often ignored by psychiatrists: the unacceptably high rates of tobacco use in patients with severe 
mental disorders. The EPA—Position Statement on Smoking and Strategies for Smoking Cessation in 
People with Mental Illness concludes that “since tobacco dependence is a dependence disorder, 
psychiatrists are the experts in performing interventions in this area. It is their duty to do so in view of 
the major impact of tobacco dependence on, for example, the metabolism of psychotropic treatments, 
morbidity (such as lung cancer) and mortality” [44]. Furthermore, the relative absence of published 
results in this field adds more value to our study. In this study we have shown that such programmes 
are feasible and can be implemented in centers treating patients with severe mental illness since 66% 
of them completed the active treatment phase. 
An advantageous feature of the study is its external validity and therefore the generalizability of our 
results. The inclusion and exclusion criteria used allowed us to enrol “real world” patients seen in daily 
clinical practice. Only those patients with an acute exacerbation of their mental illness or in whom the 
three study drugs were contraindicated were excluded from the study. Although we utilized the 
Spanish version of the URICA test [53] to identify each patient's stage of change according to the 
Prochaska and DiClemente Model [64], this information was not considered an inclusion or exclusion 
criterion due to the lack of Spanish normative scores or cutoff scores, data in people with severe 
mental disorders, and published doubts about its usefulness [66,67]. We hope to identify whether any 
of the stages of change is associated with higher rates of smoking cessation. 
Another strength of this study is the sample size. Although 82 patients is not a very large sample, to 
our knowledge the majority of the published studies in patients with severe mental disorders included 
far fewer patients or were case reports. However, the lack of a control group may be considered an 
important shortcoming. The open-label design of the study could be also considered a limitation of the 
study. However, this study was intended to be a pragmatic trial of the effectiveness of a multi-component 
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programme specifically designed for individuals with severe mental disorders rather than a clinical 
trial designed to determine the comparative efficacy of the approved drugs for smoking cessation.  
One strong point of our study in comparison with other smoking cessation studies is the 
comprehensive clinical evaluation that was done. In addition to taking an exhaustive smoking history 
we assessed the use of other substances, the psychopathology severity including suicidal thoughts and 
behaviours, and adverse events using validated psychometric instruments. Standard laboratory tests 
were also performed. Conversely, a weak point is the lack of collection on somatic comorbidities. 
However, since we have anthropometric data and laboratory results we can obtain information on 
obesity, metabolic syndrome and cardiovascular risk, the most frequent somatic comorbidities in these 
patients and highly associated with their premature mortality. 
Finally, the McSCSP was developed with the aim of providing mental healthcare professionals with 
an intervention that could be applied in specialized routine clinical practice. It may be said that  
60 to 75 min is too long for implementation in standard mental health centres. However since it is 
designed for use in severely ill patients in specialized medical facilities (psychiatric units),  
and given the potential benefits to both the healthcare system and patients, as well as the group 
modality of the intervention (60–75 min for 6 to 8 patients), this should not constitute a barrier,  
or worse, an excuse not to address the problem. This will be of interest if we are able to demonstrate 
that our smoking cessation programme is safe and effective in patients with severe mental disorders 
and should thus be disseminated for use in everyday clinical practice in Spain. 
4. Conclusions  
The prevalence rate of tobacco dependence among patients with severe mental disorders is about 
twice that of people without these disorders. In addition, tobacco is one of the most important 
avoidable factors contributing to the high rates of morbidity and mortality seen in these patients. 
Therefore, psychiatrists, clinical psychologists and psychiatric nurses, as experts in addiction 
treatment, should motivate and help their patients to quit smoking 
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